Extent of disease ‐ CT scan (lower score = better) · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Generic quality of life measures · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐5 mAb (mepolizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Disease‐specific quality of life · patients with chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Disease severity, as measured by validated, patient‐reported symptom score · patients with chronic rhinosinusitis with nasal polyps
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · patients with chronic rhinosinusitis with nasal polyps
It is very uncertain whether anti‐IgE mAb (omalizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).
1 finding from 1 review
Disease severity ‐ VAS (range 0 to 10, lower = better) · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Avoidance of surgery Nasal polyp score ≤4 (≤ 2 on each side) and an improvement in SNOT‐22 score of ≥ 8.9 points · patients with chronic rhinosinusitis with nasal polyps
Anti‐IgE mAb (omalizumab) may leads to higher avoidance of surgery Nasal polyp score ≤4 (≤ 2 on each side) and an… compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Extent of disease ‐ endoscopic score · patients with chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Extent of disease ‐ CT scan (lower score = better) · patients with chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Generic quality of life measures · patients with chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Adverse events ‐ nasopharyngitis, including sore throat · patients with chronic rhinosinusitis with nasal polyps
Anti‐IgE mAb (omalizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Serious adverse events · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐4Rα mAb (dupilumab) may leads to lower serious adverse events compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Avoidance of surgery ‐ number of patients who had surgery as rescue treatment · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐4Rα mAb (dupilumab) probably leads to lower avoidance of surgery ‐ number of patients who had surgery as rescue… compared with placebo (on top of topical steroids) (moderate certainty).
1 finding from 1 review
Extent of disease ‐ endoscopic score · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Extent of disease ‐ CT scan (lower score = better) · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Generic quality of life measures · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐4Rα mAb (dupilumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat (longest… compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review